Has Peter Mavrelis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $12,731 in general payments to Peter Mavrelis, MD across 158 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Peter Mavrelis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Peter Mavrelis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Peter Mavrelis, MD

Gastroenterology · Hobart, INNPI 1326043597

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,600 of the $12,731 with a category attached, or 67.6%. Salix Pharmaceuticals, A Division Of Bausch Health US, LLC accounts for 87.1% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $11,867 and has fallen 98.7% since, to $153 in 2021.

$12,731in general payments, 2019–2025

Across 158 payments — averaging $80.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$11K
AbbVie$467
Gilead$256
Takeda Pharmaceuticals U.S.A., Inc.$184
Endogastric Solutions, Inc$145
Pfizer$85
plus $500 from 13 others

$14,650in research payments, 2019–2025

Across 7 payments — averaging $2092.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Pfizer$15K

What the payments were for

Speaking & faculty fees$8,60068%
Travel & lodging$1,29310%
Food & beverage$2,78822%
Education$500%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	54	$11,092
AbbVie(2 entities)	28	$467
Gilead	25	$256
Takeda Pharmaceuticals U.S.A., Inc.	12	$184
Endogastric Solutions, Inc	2	$145
Pfizer	7	$85
Shionogi Inc	4	$75
UCB, Inc.	4	$64
Intercept Pharmaceuticals, Inc.	4	$64
Nestle Healthcare Nutrition Inc.	2	$54
Merck	3	$39
Redhill Biopharma Inc.	2	$38
Mylan Specialty L.p.	2	$34
Johnson & Johnson	2	$28
Ferring Pharmaceuticals Inc.	2	$26
Alfasigma USA, Inc.	2	$25
Advanced Respiratory, Inc	1	$22
Vivus LLC	1	$18
Evoke Pharma, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TRULANCE$10,018
XIFAXAN$200
Epclusa$125

How this compares

$12,731 in reported general payments places this provider in the 85th percentile of 323 gastroenterology providers in Indiana.

See all gastroenterology providers in Indiana →

Medicare billing

Part B allowed, 2024

$25,358

Medicare patients

125

Services billed

170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gastroenterology in Hobart

Douglas RexIndianapolis$557K
Ajay JainIndianapolis$432K
Jonathan ObertNew Albany$302K
Monika FischerIndianapolis$258K
Naga ChalasaniIndianapolis$255K
Matthew BohmWestfield$239K
Thomas ImperialeIndianapolis$188K
Mark GromskiIndianapolis$154K
David PoundIndianapolis$137K
Anoop AppannagariMunster$120K

See the full list for Indiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →